Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Details of the settlement are confidential.ABBOTT PARK, Ill., Dec. 23, 2024 -- Abbott announced today it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.
伊利諾伊州雅培公園，2024年12月23日——雅培今天宣佈，它已與DexCom, Inc.達成協議，以解決兩家公司之間在與連續血糖監測產品有關的案件中所有懸而未決的專利糾紛。
The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. There are no financial payments associated with the settlement from either Abbott or Dexcom.
該協議將導致全球法院和專利局的所有未決案件被駁回。它還包括一項條款，即雙方在未來10年內不得相互提起專利、商業外觀和外觀設計權糾紛訴訟。雅培或德克斯康均未支付與和解相關的財務款項。
Abbott considers this agreement a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services.
雅培認爲該協議是一項積極的進展，因爲它使公司能夠全神貫注於通過其技術和服務爲糖尿病患者提供支持。
Details of the settlement are confidential.
和解的細節是保密的。
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube.
關於雅培：
Abbott 是全球醫療保健領導者，致力於幫助人們在生命的各個階段過上更充實的生活。我們的改變生活的技術組合涵蓋醫療保健領域，在診斷、醫療器械、營養品和品牌仿製藥方面擁有領先的業務和產品。我們的 114,000 名同事爲 160 多個國家的人們提供服務。通過領英、臉書、Instagram、X 和 YouTube 聯繫我們。
For further information: Abbott Media: Kate Dyer, (224) 668-9965; Abbott Financial: Michael Comilla, (224) 668-1872
欲了解更多信息：雅培媒體：凱特·戴爾，（224）668-9965；雅培金融：邁克爾·科米拉，（224）668-1872
譯文內容由第三人軟體翻譯。
